Drug Research
Berkshire Sterile Manufacturing Expands Testing & Development Capabilities
Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish CDMO, recently purchased and validated three new analytical instruments to expand its testing and development capabilities.
While the company’s primary service offering is sterile filtration and filling of parenterals, BSM also provides...
Drug Research
Micro-Sphere Launches R&D Lab in Switzerland
Global contract development and manufacturing organization Micro-Sphere has launched a new, 200 square-foot research and development (R&D) lab to strengthen its services in formulation development and inhalation.
Located within its facility in Monteggio, Switzerland, the new R&D department will specialize...
Drug Research
Asymchem Opens New R&D Site Near Boston
Asymchem Laboratories (Tianjin) Co. Ltd., a CDMO serving the global pharmaceutical and biotech industry, has opened a new site in Woburn, Massachusetts.
Asymchem Boston, a wholly owned subsidiary of Asymchem Group, marks an important step toward expanding Asymchem's global footprint....
Drug Research
Stem Cell Transplant May Halt The Onset of MS Disability
An Italian study that was recently published in Neurology, the official journal of the American Academy of Neurology, suggests that hematopoietic stem cell transplants may help persons having active secondary progressive multiple sclerosis (MS) delay disability.
The ten-year retrospective study...
Drug Research
FDA, Research Issues Addressed By Major Federal Budget Bill
Multiple provisions crucial to FDA operations and authority, in addition to clinical research sponsors and pharmaceutical manufacturers, are included in the year-end, must-pass government spending bill. Along with dozens of measures involving drug development and regulation, the $1.7 billion...
Drug Research
Multi Millions of Pounds In Support For Genomics Research
The benefits of earlier detection and quicker access to treatments will be felt by cancer patients as well as newborns with curable but uncommon genetic illnesses. It comes after the UK health and social care secretary pledged a £175...
Drug Research
FDA Okays First Gene Therapy For Early-Stage Bladder Cancer
The first gene therapy for non-muscle invasive bladder cancer (NMIBC) in individuals with high-risk carcinoma in situ (CIS) with or without papillary tumours has been licenced by the US Food and Drug Administration (FDA) as Adstiladrin (nadofaragene firadenovec-vncg). Adstiladrin,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















